<DOC>
	<DOCNO>NCT02353468</DOCNO>
	<brief_summary>This phase II trial study well give bortezomib , lenalidomide , dexamethasone together work treat patient multiple myeloma undergoing stem cell transplant . Bortezomib may stop growth cancer cell block enzymes need cell growth . Biological therapy , lenalidomide , may stimulate immune system different way stop cancer cell grow . Drugs use chemotherapy , dexamethasone , work different way stop growth cancer cell , either kill cell stop divide . Giving bortezomib , lenalidomide , dexamethasone together may kill cancer cell .</brief_summary>
	<brief_title>Bortezomib , Lenalidomide , Dexamethasone Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant</brief_title>
	<detailed_description>CONSOLIDATION : Patients receive bortezomib , lenalidomide , dexamethasone ( VLD ) therapy comprise bortezomib intravenously ( IV ) day 1 , 4 , 8 , 11 , lenalidomide orally ( PO ) daily ( QD ) day 1-14 , dexamethasone PO IV day 1 , 2 , 4 , 5 , 8 , 9 , 11 , 12 . Courses continue 28 day repeat every 3 month absence disease progression unacceptable toxicity . In course VLD , patient receive Lenalidomide + Dexamethasone ( LD ) therapy comprise lenalidomide PO QD day 1-21 dexamethasone PO QD IV every Monday ( x3 ) . Courses continue 28 day . MAINTENANCE : Starting third year therapy , patient receive lenalidomide PO QD day 1-14 dexamethasone PO QD IV every Monday ( x2 ) . Courses repeat every 4 week absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients symptomatic active multiple myeloma complete autotransplant eligible study ; patient assess eligibility within 35 day transplant treatment commence within 10 week transplant Performance status 02 base Southwest Oncology Group ( SWOG ) criterion ; patient poor performance status ( 34 ) also eligible , complication bone compression fracture , hyperviscosity infection pneumonia adequately treat No significant comorbid medical condition ; uncontrolled life threaten infection Unsupported platelet count &gt; 80,000/uL Absolute neutrophil count ( ANC ) &gt; 1000/uL Signed inform consent obtain patient accordance institutional federal guideline Patients history recent ( &lt; 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control significant cardiac arrhythmia , arrhythmia associate prolonged QT interval Pregnant nursing woman ; woman childbearing potential must negative pregnancy document within one week registration ; women/men reproductive potential may participate unless agree use two form effective contraceptive method Patients grade 34 neuropathy relate prior exposure bortezomib , thalidomide , agent Human immunodeficiency virus ( HIV ) positive patient Transaminases &gt; 2 x normal value Bilirubin &gt; 2 x normal value Active uncontrolled infection History significant psychiatric illness ; steroid induce psychosis</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>